Phase 1b Repeat Dose Study of DCR-AUD in Healthy Volunteers
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the safety, tolerability, pharmacokinetics (PK),
and pharmacodynamics (PD) of of repeat doses of DCR-AUD in adult healthy volunteers who are
social drinkers.
The main questions it aims to answer are:
- Are repeat doses of DCR-AUD safe and well-tolerated in healthy adults who are social
drinkers?
- How does the drug behave inside the human body and how it is removed from the human
body?
- What are the symptoms the drug may cause with alcohol consumption?
Participants will:
- Receive multiple doses of DCR-AUD.
- Have assessment visits through Week 24.
- Participate in up to 10 Ethanol Interaction Assessments (EIAs) to see how the body is
affected by DCR-AUD.
Researchers will compare the groups of participates who receive study drug with the group of
participants who receive placebo to see if the study drug is safe and tolerable and whether
the study drug has any real effect.
Phase:
Phase 1
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company